2023
Making inroads to precision medicine for the treatment of autoimmune diseases: Harnessing genomic studies to better diagnose and treat complex disorders
Baglaenko Y, Wagner C, Bhoj V, Brodin P, Gershwin M, Graham D, Invernizzi P, Kidd K, Korsunsky I, Levy M, Mammen A, Nizet V, Ramirez-Valle F, Stites E, Williams M, Wilson M, Rose N, Ladd V, Sirota M. Making inroads to precision medicine for the treatment of autoimmune diseases: Harnessing genomic studies to better diagnose and treat complex disorders. Cambridge Prisms Precision Medicine 2023, 1: e25. PMID: 38550937, PMCID: PMC10953750, DOI: 10.1017/pcm.2023.14.Peer-Reviewed Original ResearchAutoimmune diseasesPrecision medicinePathogenic autoantigenPatient subtypesDisease heterogeneityComplex etiologyMolecular profilingDiseaseAccount individual variabilityDisease mechanismsForeign cellsMolecular pathwaysNatural defense systemComplex disorderDisease treatmentHealthy tissueIndividual variabilityOwn cellsTreatmentMedicineTherapeuticsDefense systemCurrent understandingCellsAutoantigens
2018
Tumour-immune dynamics with an immune checkpoint inhibitor
Nikolopoulou E, Johnson L, Harris D, Nagy J, Stites E, Kuang Y. Tumour-immune dynamics with an immune checkpoint inhibitor. Letters In Biomathematics 2018, 5: s137-s159. DOI: 10.1080/23737867.2018.1440978.Peer-Reviewed Original ResearchProteins programmed death-1Anti-PD-1Immune checkpoint inhibitorsTumor-immune dynamicsCheckpoint inhibitorsAnti-PD-1 drugsLigand PD-L1Eradicate tumor cellsTumor immune responseFunctional immune systemAntitumour responseDeath-1PD-L1Tumor-freeControl tumorsTumor equilibriumTumor cellsClinical trialsContinuous treatmentImmune systemTreatmentTumor-immune modelInhibitorsTumorTherapy